RELEASE JUNE 11, 2005 from the Food and Drug Administration
The Food and Drug Administration (FDA) has approved Adacel, a new vaccine for a single booster
immunization against pertussis (whooping cough), in combination with tetanus and diphtheria,
for adolescents and adults 11-64 years of age.
Adacel is the first vaccine approved as a pertussis booster for adults. Vaccines for prevention
of tetanus and diphtheria (Td vaccine) in adolescents and adults have been available for many years.
Adacel is a Tetanus Toxoid (T), Reduced Diphtheria Toxoid (d) and Acellular Pertussis Vaccine (ap),
Adsorbed. Adacel contains the same components as Daptacel, a DTaP vaccine indicated for infants
and children manufactured by Aventis Pasteur Limited, but the diphtheria toxoid and one of the
pertussis components are in reduced quantities.
Recently, FDA approved a similar vaccine called Boostrix, manufactured by GlaxoSmithKline, for use
in adolescents 10-18 years of age.
Pertussis is a highly communicable and potentially serious illness in adolescents and adults,
and can cause prolonged cough and missed days at school and work. In young infants, pertussis
is more frequently severe and can be fatal, particularly in those too young to be fully vaccinated.
Since 1980, the rates of reported pertussis cases have been increasing in adolescents and adults, as
well as in young infants. Adolescents and adults have been implicated as the source of pertussis
infection for susceptible young infants, and other family members.
The ability of Adacel to protect against pertussis was assessed by comparing the antibody responses
of adolescents and adults who received it with the antibody responses of infants who had received
Daptacel in a clinical trial. The antibody responses of the adolescents and adults who received a
single dose of Adacel were at least as good as those observed in the infants following three doses of
Daptacel. For diphtheria and tetanus, the antibody responses following Adacel were comparable to those
following immunization with a U.S. licensed Td vaccine.
In clinical trials, the safety of Adacel was compared to a U.S. licensed Td vaccine. Among adolescent
recipients of Adacel, injection site pain and low grade fever were observed more frequently than among
those who received Td vaccine. Rates of adverse reactions were similar in adults receiving Adacel
vaccine or receiving Td vaccine.